Biomarker-driven Phenotypic Dissection of Amyotrophic Lateral Sclerosis

Launched by ISTITUTO AUXOLOGICO ITALIANO · Mar 15, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "Biomarker-driven Phenotypic Dissection of Amyotrophic Lateral Sclerosis," is designed to explore the different ways that Amyotrophic Lateral Sclerosis (ALS) can affect people. The researchers want to identify specific biological markers (called biomarkers) that can help explain why ALS symptoms vary from one person to another. By understanding these differences, they hope to group patients into more specific categories based on their condition, which could lead to better treatments in the future.

To participate in this study, individuals must have a diagnosis of ALS or another type of motor neuron disease and live near the study centers. Participants will undergo several evaluations, including tests for their nervous system, brain function, and genetic analysis. They will also provide samples of their blood and spinal fluid to measure the biomarkers. The study is currently recruiting participants aged 65 to 74, and it is important that those interested are willing to return for follow-up visits and consent to take part in the research. This trial aims to improve our understanding of ALS, enhancing care and treatment options for those affected by this challenging disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • diagnosis of ALS or other motor neuron disease
• • residence near the study centers
• Exclusion Criteria:
• • refusal to participate to the study
• • unable/unwilling to perform follow-up visits